Vascular AGE-ing by methylglyoxal: the past, the present and the future by unknown
COMMENTARY
Vascular AGE-ing by methylglyoxal: the past,
the present and the future
Casper G. Schalkwijk1,2
Received: 13 February 2015 /Accepted: 2 March 2015 /Published online: 12 May 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Over the years, new research has elucidated the
importance of the very fast formation of AGEs by the highly
reactivemethylglyoxal (MGO). It has become clear that MGO
triggers maladaptive responses in vascular tissue. To counter-
act the deleterious effects of MGO, organisms have an enzy-
matic glyoxalase defence system in which MGO is converted
to D-lactate, with glyoxalase 1 (GLO1) as the key enzyme in
this system. Significant progress has been made towards the
understanding of the MGO–GLO1 pathway in the pathogen-
esis of vascular disease in diabetes. This commentary high-
lights some lines of current research and future perspectives.
The work conducted so far is only the starting point—in the
coming 50 years, the MGO–GLO1 pathway will be the sub-
ject of intensified research, with special focus on pathophys-
iological pathways, the use of this system for early screening
and risk prediction, and the development of intervention strat-
egies for preventing vascular complications in people with
and without diabetes. This is one of a series of commentaries
under the banner ‘50 years forward’, giving personal opinions
on future perspectives in diabetes, to celebrate the 50th anni-
versary of Diabetologia (1965–2015).
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Nrf2 Nuclear factor-erythroid 2-related factor 2
RAGE Receptor for AGEs
The latest estimates from 2013 show that 382 million people
worldwide are suffering from diabetes and this is expected to
rise to 592 million by 2035 [1]. The burden of diabetes is
determined mainly by micro- and macrovascular endpoints.
The increased formation of AGEs has been proposed as one
mechanism that could explain the much faster development of
vascular complications in diabetic than in non-diabetic
individuals.
Traditionally, the formation of AGEs is viewed as a post-
translational modification of proteins and other macromole-
cules by reduced sugars that accumulate slowly on extracellu-
lar and long-lived proteins throughout life. This reaction was
first described in 1912 by food chemist Louis Camille
Maillard. Although Maillard suggested that these chemical
processes would be important in biology and medicine, it
was not until the early 1980s that the pathophysiological sig-
nificance of AGEs emerged in medical science [2]. Although
the formation of AGEs is a naturally occurring process
resulting from normal metabolism, it increases under
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hyperglycaemic conditions as well as under conditions of in-
creased oxidative stress and hyperlipidaemia. AGEs are not
inert; several mechanisms have been proposed to explain how
AGEs contribute to the development of pathological condi-
tions, including the aberrant crosslinking of extracellular ma-
trix proteins, which results in a decrease of elasticity in blood
vessels and leads to arterial stiffness, which is a hallmark of
vascular ageing, as well as impaired permeability and cellular
motility. In addition, AGEs bind to the cell-surface receptor
RAGE (receptor for AGEs). This binding does not accelerate
clearance or degradation but rather begins a sustained period
of cellular activation that is mediated by receptor-dependent
signalling, leading to inflammation-provoking tissue injury
(Fig. 1).
There have been dramatic transformations in AGE research
in recent years. It was long believed that AGEs only accumu-
late very slowly on long-lived extracellular proteins, but new
research has elucidated the significance of very fast AGE for-
mation on cellular and short-lived extracellular proteins, lipids
and DNA, with the highly reactive methylglyoxal (MGO) as a
key compound involved in the very fast generation of
glycation adducts [3]. MGO has been linked to a range of
detrimental effects on cellular function, including increased
oxidative stress. To counteract these effects, organisms have
an enzymatic glyoxalase defence system that catalyses the
conversion of MGO to D-lactate. Glyoxalase 1 (GLO1) is
the key enzyme in this system and is a major line of defence
against glycation. In recent years, remarkable progress has
been made towards understanding the glyoxalase pathway,
and MGO in particular, with the development of specific
and sensitive methods for the assay of MGO [4], the demon-
stration that MGO is mainly generated as a byproduct of gly-
colysis and the demonstration that MGO is the most potent
glycation agent [3]. The aim of this commentary is to further
highlight the potential importance of MGO and GLO1 in risk
prediction, pathogenesis and intervention in vascular disease
in people with diabetes. Some lines of current research and
future perspectives are debated.
MGO and risk prediction of vascular disease
With increasing incidence of diabetes, the early detection of
vascular disease continues to be a great challenge for clini-
cians in the 21st century. Despite the development of integrat-
ed risk scores for vascular disease, it is still very difficult to
precisely estimate which individuals will develop vascular
disease and which individuals will remain event-free. Even
the extent to which high glucose levels in diabetic patients,







































Fig. 1 Biology of MGO: MGO is mainly formed as a byproduct of
glycolysis. Increased levels of MGO are predominantly detoxified by
GLO1, the key enzyme in the glyoxalase system, which converts MGO
to D-lactate. Type 2 diabetes is associated with higher MGO incremental
AUC, calculated from OGTT. MGO is involved in epigenetics and oxi-
dative stress, and reacts, intracellularly and extracellularly, with arginine
residues in proteins to produce MG-H1, the most important MGO-de-
rived AGE. MG-H1 is cleared by lysosomal degradation. MGO modifi-
cations lead to protein inactivation, and changes in functionality and
binding affinity to RAGE, resulting in maladaptive responses in vascular
tissue. DHAP, dihydroxyacetone phosphate; G3P, glyceraldehyde
3-phosphate; GSH, glutathione
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to vascular disease remains controversial. Recent studies have
suggested that postprandial spikes of high glucose may be a
more robust determinant of vascular risk than average glucose
levels as determined by HbA1c. However, we should recog-
nise that HbA1c levels are unlikely to provide a fully accurate
picture of temporal glycaemic fluctuations, and thus to
discriminate between diabetic individuals with and without
regular occurrences of hyperglycaemic spikes. This may be
one of the underlying reasons why glycaemic control, as mea-
sured by decreasing HbA1c levels, has not been consistent in
successfully reducing vascular disease.
Epidemiological studies support this concept, showing that
glucose levels after an OGTT are an independent risk factor
for cardiovascular disease (CVD), while fasting glucose levels
are not, or are less so [5]. The formation of MGO might be a
possible mechanism that causes repeated glucose spikes to
have a more damaging effect than high fasting or mean glu-
cose levels on endothelial cells and the development of vas-
cular complications. We recently found that the presence of
both impaired glucose metabolism and newly diagnosed type
2 diabetes were significantly associated with higher plasma
MGO incremental AUC, as calculated by OGTT [6]. MGO
levels would be expected to increase still further in individuals
with known type 2 diabetes. Because experimental research
has demonstrated that an excess of MGO initiates and aug-
ments retinopathy, nephropathy, neuropathy and atherosclero-
sis, it is conceivable that the effect of postprandial glucose
spikes on vascular disease is due, at least partly, to MGO. If
this is the case, MGO is a strong candidate for use as a more
robust clinical marker of glycaemic fluctuation than HbA1c.
MGO is derived from glucose but is up to 20,000 times more
reactive with proteins. A major challenge for the future would
be to systematically analyse MGO-modified proteins in order
to identify one that is a better risk predictor than HbA1c.
Data from a recent cohort study have demonstrated that
increased MGO-derived AGEs are associated with an in-
creased risk for cardiovascular events in type 2 diabetic pa-
tients [7]. Furthermore, a large integrative genomic study
identified GLO1 as a causal molecular mechanism in the de-
velopment of CVD [8]. Whether we can improve risk predic-
tion for vascular disease by including components of the
MGO–GLO1 pathway in the risk engineering scores remains
a key issue. A careful cataloguing of the proteomic alterations
caused by MGO is likely to speed up the development of
predictive biomarkers for vascular disease [9]. When
we succeed in unravelling the MGO proteome, it will be an
enormous boost for the early detection of vascular disease.
Another task for the coming decade is implementing new
imaging tools to detect specific and well-characterised AGEs,
as well as MGO, at the sites of complications. The technolog-
ical progress in mass spectrometry imaging (MSI) provides
these innovative possibilities. Using MSI to detect and quan-
tify MGO, AGEs and GLO1 in human tissues within their
histological contexts will provide unique insights into the role
of AGEs in the pathogenesis and management of chronic
diseases.
MGO as a key factor in vascular complications
Although there is now considerable scientific evidence that
MGO engenders the development of vascular complications,
further research is needed to pinpoint the underlying causal
mechanisms. MGO reacts predominantly with arginine res-
idues on proteins, with methylglyoxal hydroimidazolone
(MG-H1) being the most prevalent MGO-derived AGE
modification found in vivo, leading to the structural change,
inactivation and degradation of target proteins.
Several studies have shown a downregulation of GLO1 not
only in the context of hyperglycaemia, but also in inflamma-
tory signalling [10], hypoxia [10] and ageing [11], and this is
accompanied by increased levels of MGO, indicating that this
pathway is not only key for diabetic complications, but also
for other age-related diseases such as atherosclerosis [10]].
The decline in GLO1 activity in arterial tissue may contribute
directly to an increased risk of CVD with ageing. It is becom-
ing clear that the glyoxalase and RAGE pathways are
intertwined. MG-H1 has a very high (nanomolar) affinity for
RAGE, while the binding of the best-characterised AGEs (i.e.
Nε-(carboxymethyl)lysine-containing peptides) to RAGE is
weak and in the micromolar range [12]. Various MG-H1
modified proteins as well free MG-H1 in tissue and plasma
can bind to RAGE. The fact that the peptide backbone of the
MG-H1-containing proteins is not involved in RAGE binding
indicates that RAGEmay act as a pattern recognition receptor.
The RAGE-dependent downregulation of GLO1, which leads
to increased MG-H1 formation on various proteins, will ulti-
mately lead to further ligation and activation of RAGE, and to
a continued and self-perpetuated inflammatory response.
Targeting the formation of MGO and the RAGE interaction
may therefore provide a novel therapeutic strategy in treating
micro- and macrovascular complications and contribute to
‘successful vascular ageing’. This will be a topic to explore
in the coming years.
To date, efforts to treat vascular complications have been
hampered by ‘metabolic memory’, a phenomenon in which
prior exposure to hyperglycaemia predisposes diabetic pa-
tients to the continued development of vascular disease, which
persists even after improved glycaemic control. One possible
explanation for this metabolic memory is that prolonged epi-
genetic changes in tissues lead to persistent changes in the
expression of the genes associated with diabetic vascular com-
plications. In addition to the modification of histones, changes
in methylation patterns of the DNA itself have been described
in the context of diabetes and epigenetic changes, and may
also contribute to the development of metabolic memory. As
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stated, MGO has not only been linked to the modification of
proteins, but has also been shown to directly modify and dam-
age DNA. Indeed, a first link between the accumulation of
MGO and the development of an epigenetic memory has been
made [13]. Since epigenetic changes form the basis of many
diseases, managing MGO levels could be the key to
preventing multiple vascular complications.
MGO as a target for intervention
From a clinical point of view, reducing the accumulation of
MGO and enhancing GLO1 activity could provide new ther-
apeutic opportunities for minimising the pathophysiological
modifications associated with increased levels of MGO.
Because MGO is mainly formed by the degradation of triose
phosphate intermediates in glucose metabolism, improving
metabolic control and reducing hyperglycaemia may be a first
step in reducing the accumulation of MGO. Fortunately, new
approaches to lowering glucose excursions have been de-
veloped, including the bionic pancreas, sodium–glucose
co-transporter 2 (SGLT2) inhibitors and dipeptidyl
peptidase-4 (DPP-4) inhibitors. Preliminary studies suggest
benefits for cardiovascular risk, and it will be interesting to
explore whether their mechanisms of action seem to be
dependent on the reduction of MGO.
Several more pharmacological interventions have
been developed to inhibit the accumulation of MGO,
of which pyridoxamine is regarded as the most promising.
Other potential treatments include arginine-containing
peptides [14]. However, the strong affinity of MGO with
arginine residues in vivo is a point of concern, and it is
important to determine whether the effective affinity of pyri-
doxamine and arginine-containing peptides forMGO is strong
enough to compete with endogenous arginine residues.
Another treatment strategy for reducing MGO is the use of
GLO1 inducers. Since GLO1 expression is mediated via
nuclear factor erythroid 2-related factor 2 (Nrf2) binding to
the antioxidant responsive element (ARE) in the GLO1 pro-
moter, activators of this Nrf2 transcription system are impor-
tant for ongoing studies. Isothiocyanates, including sulforaph-
ane, are interesting in this regard. These compounds, which
can be found in cruciferous vegetables, are known to activate
Nrf2. It has been demonstrated that Nrf2 activators increase
the levels of GLO1 expression and decrease cellular and
extracellular concentrations of MGO and MGO-derived
protein adducts, while also reducing mutagenesis and
cell detachment [15]. These findings highlight the importance
of the regulatory increase in cell defences against MGO via
the Nrf2–ARE–GLO1 pathway. Dietary bioactive inducers of
GLO1 could therefore be used for patients with ageing-related
disorders in which MGO plays a pivotal role.
A century ago, non-enzymatic glycation and the
glyoxalase system were discovered. Over the years, it
has become clear that MGO triggers maladaptive re-
sponses in vascular tissue. Over the coming 50 years,
MGO, MGO-derived AGEs and the glyoxalase system
will be subjects of intensified research, with particular
focus on pathophysiological pathways, the use of this
system for early screening and improving risk predic-
tion, and the development of intervention strategies for
preventing vascular complications in people with and
without diabetes. The work carried out so far is only
the starting point. Hopefully, 50 years from now we
will know exactly how to decrease the burden of diabe-
tes and its complications.
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